PGEN

Announcements

Nothing here yet

Daily updates

• Precigen secured an FDA Platform Technology Designation for its AdenoVerse gene therapy platform, supporting PAPZIMEOS for recurrent respiratory papillomatosis and potentially enabling regulatory efficiencies for future pipeline candidates.Sep 21, 2026

FDA designations

Nothing here yet

News

• Precigen received FDA platform technology designation for its AdenoVerse platformSep 21, 2026
• Precigen gained orphan drug exclusivity for PAPZIMEOS from the FDA and reported encouraging long-term clinical dataJun 15, 2026
• Expert consensus recommends PAPZIMEOS as first-line treatment for respiratory papillomatosisJan 20, 2026
• Precigen announces long-term follow-up results highlighting ongoing durable complete responses after treatment with PAPZIMEOS, the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosisOct 13, 2025
• Precigen announces full FDA approval of PAPZIMEOS, the first and only approved therapy for adults with recurrent respiratory papillomatosisAug 15, 2025